Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans

NCT02718950 · Unknown status

Last updated 2026-05-28

This clinical trial tests whether the medication liraglutide, which is used to treat obesity and type 2 diabetes, affects the activity of brown fat in adults with these conditions.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 20 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2016-06 · est. completion 2017-04

What this study is testing ClinicalTrials.gov NCT02718950 ↗

Description as written by the study sponsor.

The purpose of this study is to access liraglutide influence brown adipose tissue recruitment and its thermogenic effect through hypothalamic activation in obese individuals.

Treatments tested

Liraglutide 3.0 mg also known as Victoza Drug

Subjects will use liraglutide 3.0 mg for 2 weeks

Main thing measured	Evaluate the effect of liraglutide administration on brown adipose tissue (BAT) activation in humans
Sponsor	University of Campinas, Brazil
Conditions studied	Obesity, Type 2 Diabetes Mellitus
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02718950 ↗